GlassScriptPhysician profile
Neil S Seif
NPI 1316077662
$920.85
in general payments reported to CMS, 2019-2025
21 companies · $23.60 in 2025
The $23.60 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $141 · 2021: $98.04 · 2022: $51.47 · 2023: $20.40 · 2024: $60.29 · 2025: $23.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.80 | 2019-2024 | Tagrisso |
| Merck Sharp & Dohme LLC | $150.54 | 2019-2020 | |
| Genentech USA, INC. | $89.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.11 | 2019 | |
| Seagen INC. | $64.45 | 2021-2023 | Tukysa |
| Celgene Corporation | $51.34 | 2019 | |
| Exelixis INC. | $30.40 | 2019 | |
| Medtronic USA, INC. | $26.26 | 2019 | |
| Lantheus Medical Imaging, INC. | $24.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.71 | 2020 | |
| Boston Scientific Corporation | $24.55 | 2024 | Superion Indirect Decompression System |
| Servier Pharmaceuticals LLC | $23.60 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $22.51 | 2020 | |
| Eisai INC. | $21.10 | 2021 | |
| Astellas Pharma US INC | $20.93 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $20.21 | 2024 | Fruzaqla |
| Taiho Oncology, INC. | $20.12 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.73 | 2019 | |
| Genzyme Corporation | $17.27 | 2021 | |
| Epizyme, INC. | $16.66 | 2021 | |
| Lilly USA, LLC | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Seif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.